Skip to main content

Table 4 The summary of subgroup analyses

From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Subgroup analysis Subjects
SGLT-2 inhibitors GLP-1 RAs Comparison Risk ratio 95% CI I2 (%) p value
MACE-3
 eGFR 30-44 2479 1934 SGLT-2 inhibitors vs. placebo 0.73 0.54–0.97 57.1 0.063
   GLP-1 RAs vs. placebo 1.02 0.78–1.33   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.72 0.48–1.06   
 eGFR 45-59 3974 4576 SGLT-2 inhibitors vs. placebo 0.82 0.66–1.01 44.8 0.12
   GLP-1 RAs vs. placebo 0.85 0.71–1.03   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.96 0.72–1.27   
Renal outcomes
 eGFR 30-44 2420 889 SGLT-2 inhibitors vs. placebo 0.75 0.62–0.91 0 0.69
   GLP-1 RAs vs. placebo 0.78 0.46–1.32   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.96 0.55–1.29   
 eGFR 45-59 3976 2288 SGLT-2 inhibitors vs. placebo 0.61 0.48–0.77 0 0.52
   GLP-1 RAs vs. placebo 1.18 0.76–1.84   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.52 0.31–0.85   
  1. SGLT2i sodium-glucose cotransporter-2 inhibitors, GLP-1 RAs glucagon-like peptide-1 receptor agonists, eGFR estimated glomerular filtration rate, CI confidence intervals, MACE-3 3-point major adverse cardiovascular event, vs. versus, N/A not available